抄録 Two patients with non-small cell lung cancer presented with multiple brain metastases.
They received gefitinib orally for the treatment of the primary lung lesions. About one month …

Two patients with non-small cell lung cancer presented with multiple brain metastases. They
received gefitinib orally for the treatment of the primary lung lesions. About one month later …

A woman with stage IIIb non-small cell lung cancer (NSCLC) developed disease
progression with brain metastases during chemotherapy. Due to unusual circumstances, the …

The clinical efficacy of gefitinib, a tyrosine kinase inhibitor of epidermal growth factor
receptor (EGFR), on brain metastases (BMs) from non–small-cell lung cancer (NSCLC) was …

Two Japanese women were diagnosed as having welldifferentiated adenocarcinoma of the
lung with brain metastases. Since it was considered they could not tolerate conventional …

We report two cases of central nervous system metastases from non-small cell lung cancer
in patients being administered gefitinib, which improved after changing treatment to erlotinib …

Case 1 is a 78-year-old woman in whom lung adenocarcinoma with multiple brain
metastasis (cT2N3M1, stage IV) was diagnosed. She was treated with Gefitinib alone. Her …

Brain metastases are a frequent finding in patients with non-small cell lung cancer (NSCLC).
The present case reports the clinical course of a patient who was treated with gefitinib alone …

Leptomeningeal metastasis occurs in approximately 1% of patients with non-small cell lung
cancer and this is an extremely serious complication. Without treatment, the median survival …

Gefitinib is the first inhibitor of the epidermal growth factor receptor that has shown activity in
non–small-cell lung cancer (NSCLC), but its potential value in the treatment of central …